Careers  |   Log In  |   Register  |   Welcome Center  |   Follow Us  Facebook  Twitter Google Plus

Latest in Oncology

Current therapeutic options for non-small cell lung cancer (NSCLC) are ever-evolving with the possibility of solely immunotherapy-based treatment regimens on the near horizon for certain patients.
Magnetism is leveraged for site targeting, medicine delivery, and efficacy monitoring with this new nanoparticle technology.
The AUA has teamed up with ASCO, ASTRO, and SUO to provide new guidelines for non-metastatic MBIC treatment.